The main objective of the Incubator grant program is to stimulate the activity of scientists towards the realisation of research projects that, in addition to their scientific value, may also have commercial potential. Twelve projects were submitted in this year’s edition, which was evaluated by an Investment Committee made up of business representatives with experience in the medical and biotechnology sectors.

Funding was awarded to three projects:

• In vivo studies and the development of a prototype of a potential new-generation anticancer drug Graph-2-ME based on graphene for topical therapy of advanced skin tumours, which will be implemented under the direction of Dr. Habil. Magdalena Górska-Ponikowska, Assoc. Prof., the Head of the Department of Medical Chemistry, in cooperation with the team of Prof. Ewa Iżycka-Świeszewska, the team of Prof. Tomasz Bączek and Grażyna Peszyńska-Sularz, V.M.D. from the Tri-City University Animal House – Research Service Centre,

• Evaluation of acute and chronic toxicity of modified oxysterol CF3-7α,25OHC, and barbarian in vivo, by the team of Aleksandra Rutkowska, Ph.D. deputy Head of research, Brain Disease Centre,

• Production of a gain-of-function variant of the C2 protein of the complement system in a bacterial expression system led by Dr. Habil. Marcin Okrój, Assoc. Prof. of the university’s Division of Cell Biology and Immunology.

Congratulations to the winners!

The Incubator is implemented by the Technology Transfer Office of the MUG.. Additional information about the winning projects is available on the unit’s website.